Injection Site Rotation: What the Evidence Shows and How to Track It

Site rotation is the one piece of injection advice that is both universally repeated and genuinely well evidenced — though the evidence comes from somewhere other than where most people assume. It is worth separating what is established from what is extrapolated, because the gap changes how confidently you should hold the advice.

What actually goes wrong

Repeated subcutaneous injection into the same small area causes lipohypertrophy: a thickened, rubbery swelling of fat tissue under the skin. It is not a bruise and not scarring. It develops gradually, it is often easier to feel than to see, and it is frequently missed unless someone deliberately palpates for it.

Two things follow from it, and the second is the one that matters:

• It is cosmetically persistent. Lipohypertrophic tissue can take many months to resolve after injections into it stop, and may not fully resolve.
• It absorbs erratically. This is the real problem. Injecting into affected tissue produces variable and often reduced uptake — the same dose behaves differently from one day to the next.

That second point reframes rotation entirely. It is not primarily a skin-care measure. It is what keeps a dose meaning the same thing each time you take it. A protocol you are following carefully, logged accurately, can still produce inconsistent results purely because the tissue changed underneath it — and nothing in your log would show why.

Where the evidence comes from

Almost all of it comes from insulin, not from peptides. That literature is large, clinical, and unusually consistent: prevalence surveys across thousands of insulin-injecting patients repeatedly find lipohypertrophy in a substantial fraction, and find it strongly associated with two behaviours — failure to rotate sites, and reuse of needles. The 2016 FITTER injection-technique recommendations, developed from that body of work, made structured rotation a core recommendation.

The honest caveat: this is an extrapolation to peptides. The mechanism is physical and tissue-level rather than anything specific to insulin as a molecule, and the injection route, needle type and depth are the same, so the extrapolation is a reasonable one. But it is still an extrapolation, and nobody has run the equivalent prevalence studies in people injecting research peptides. Treat it as well-founded rather than proven.

One difference does cut in a helpful direction: most peptide protocols involve far fewer injections per week than intensive insulin therapy, which means less cumulative exposure per site. That reduces the risk, it does not remove it — and the compounds most often run for months at a time, like BPC-157 daily or a secretagogue pairing dosed one to three times a day, are exactly the ones where injection counts add up. Both of those are research-use-only compounds with no approved human dose; naming them here describes how often people inject, not a suggestion to.

A rotation scheme you can keep

The schemes that fail are the ones requiring you to remember an unstructured history. The ones that work impose an order you can follow without recall.

1. Pick your regions. Abdomen (avoiding a radius around the navel), outer thighs, and the upper outer buttock area are the usual subcutaneous sites. Which regions are appropriate depends on the compound and the route — check with a clinician rather than assuming any site suits anything.
2. Divide each region into a grid. Quadrants are enough. You are aiming for spacing on the order of a couple of centimetres between consecutive injections, not precision.
3. Move systematically, not randomly. Work through one region in order before moving to the next. Random selection feels like rotation and reliably over-samples the spots that are easiest to reach.
4. Give each site real time off. The point of the grid is that a specific spot is not revisited for weeks rather than days.
5. Use a fresh needle every time. Needle reuse is independently associated with lipohypertrophy in the insulin data, separately from rotation.
6. Feel for changes. Periodically palpate the sites you use. You are checking for thickened or rubbery areas. Anything you find should be taken out of rotation, and is worth showing to a clinician.

Why this belongs in the log

A rotation scheme is only as good as your memory of where you last injected, and that memory is worse than people expect — particularly with a multi-compound protocol where two or three injections happen in a session.

Recording the site turns rotation from a recollection into a record. It also makes an otherwise invisible pattern visible after the fact: if results drift over a run, a log showing that the last three weeks all landed in the same quadrant is an explanation you would never have recovered otherwise. Absent that column, tissue effects and compound effects are indistinguishable in your own data.

This is the one field most likely to be skipped, because it feels like the least quantitative thing in the entry. It is also the only one you cannot reconstruct later. A dose you can recompute from the vial; a site is gone the moment you forget it.

What to record

Alongside the dose in micrograms, the concentration and the unit count, add the site with enough specificity to distinguish repeats: “left abdomen, lower outer” rather than “stomach”. Note anything you felt at the site — tenderness, a lump, unusual resistance — at the time, not later.

“250 mcg — 5 u at 5 mg/mL, left abdomen lower outer, vial opened 12 Jun” is a complete entry. It tells you the dose, lets you verify the arithmetic, and lets you see the rotation pattern at a glance across a month. Storage and handling for the vial that dose came from are covered in the storage guide, and every compound in the library lists its routes.